Get the Stockscreener App
33.58
0.07%
0.46
Quince Therapeutics Inc stock is traded at $33.58, with a volume of 32,641.
It is up +0.07% in the last 24 hours and up +80.43% over the past month.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
See More
Previous Close:
$34.04
Open:
$34.95
24h Volume:
32,641
Relative Volume:
0.61
Market Cap:
$33.99M
Revenue:
-
Net Income/Loss:
$-33.04M
P/E Ratio:
-3.6892
EPS:
-9.1023
Net Cash Flow:
$-39.66M
1W Performance:
+11.14%
1M Performance:
+80.43%
6M Performance:
-7.93%
1Y Performance:
-89.92%
1-Day Range:
$33.08
$35.41
1-Week Range:
$30.04
$35.41
52-Week Range:
$15.10
$909.98
Quince Therapeutics Inc Stock (QNCX) Company Profile
Name
Quince Therapeutics Inc
Sector
Industry
Phone
415-910-5717
Address
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
33.42 | 34.62M | 0 | -33.04M | -39.66M | -9.1023 |
VRTX
Vertex Pharmaceuticals Inc
|
515.89 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.79 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.45 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.83 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.81 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Aug-05-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-24-25 | Initiated | Oppenheimer | Outperform |
Quince Therapeutics Inc Stock (QNCX) Latest News
Quince Therapeutics plans special meeting to vote on share issuance and potential change of control - Investing.com
Form 8K Quince Therapeutics Inc For: 17 August By Investing.com - Investing.com Canada
Quince Therapeutics to seek shareholder OK for Series C conversion, adding ~11M shares and reclassifying $6.3M warrants - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Ikarian Capital discloses 9.0% Quince Therapeutics (QNCX) ownership in Schedule 13G - Stock Titan
Nantahala Capital (QNCX) reports 0% stake in Quince Therapeutics in latest 13G/A - Stock Titan
Quince Therapeutics (QNCX) books $39.6M loss but lifts cash to $116M - Stock Titan
Quince Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Quince Therapeutics, Inc. (NASDAQ: QNCX) Stock Price, News & Analysis - Kalkine
Quince Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Cormorant Asset Management (QNCX) reports 9.99% Quince Therapeutics stake via convertibles - Stock Titan
Quince Therapeutics Q2 EPS of $(12.31) beats $(26.32) estimate - scanx.trade
Quince Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Quince Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Quince Therapeutics Reports Second Quarter 2026 Financial Results And Corporate Update - TradingView
Quince Reports $75.5 Million Second Quarter Net Loss After Orphai Deal - Quiver Quantitative
QNCX: Orphai acquisition, $115M financing, and LAM-001 trial progress define a pivotal Q2 2026 - TradingView
Quince Therapeutics reports $75.5M Q2 net loss, $116M cash as of June 30, 2026 - TradingView
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update - The Manila Times
Quince Adds Inhaled Rapamycin Program for Pulmonary Diseases - Stock Titan
Quince Therapeutics (QNCX): Balyasny group discloses 9.99% beneficial stake cap - Stock Titan
Quince Therapeutics (QNCX) Pushes Higher, Up 3.68% as Shares Test Key Resistance at $34.03Earnings Sentiment - dars.gov.et
Quince Therapeutics, Inc. expected to post a loss of $17.88 a shareEarnings Preview - TradingView
Quince Therapeutics (QNCX) sees Squadron group report 5.6% ownership stake - Stock Titan
QNCX Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Quince Therapeutics Inc (QNCX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Quince Therapeutics Announces Leadership Transition to Orphai Team - The Globe and Mail
Form S-3 Quince Therapeutics For: 31 July By Investing.com - Investing.com Canada
Quince Therapeutics (QNCX) seeks approval for Orphai merger dilution and $115M PIPE - Stock Titan
QNCX Initiated by Oppenheimer -- Rating Set to Outperform with $82 Target - GuruFocus
Oppenheimer Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $82 - Moomoo
Quince Therapeutics Inc (QNCX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Quince Therapeutics Inc (QNCX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TradingKey - TradingKey
Quince Therapeutics Inc (QNCX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Quince Therapeutics Inc (QNCX) Institutional Confidence - TradingKey
Quince Therapeutics Inc (QNCX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Quince Therapeutics Inc (QNCX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Quince Therapeutics Inc (QNCX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Quince Therapeutics, Inc. Revenue Breakdown – NASDAQ:QNCX - TradingView
QNCX|Quince Therapeutics Inc|Price:17.740|Chg%:-0.540 - TradingKey
QUINCE THERAPEUTICS INC (QNCX) Stock Chart - ChartMill
Quince Therapeutics Inc. Q1 2026 Earnings: Massive EPS Surprise Driven by One-Time GainEarnings Forecast Report - dars.gov.et
QNCX Q1 2026 Earnings: Stunning EPS Surprise of 210.29% as Company Reports $57.6 Per Share - dars.gov.et
$Quince Therapeutics (QNCX.US)$ - Moomoo
Quince Therapeutics Surges Over 11% as Biotech Momentum BuildsAdvance Decline Line - dars.gov.et
QNCX Q1 2026 Earnings: EPS Surges to $57.6, Crushing Estimates Amid Strong Stock Reaction - dars.gov.et
Quince Therapeutics updates its strategy as a clinical-stage biotech. QNCX focuses on targeted drug - Ad Hoc News
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives - The National Law Review
QNCX Should I Buy - Intellectia AI
What date does Quince Therapeutics, Inc.'s (QNCX) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Quince Therapeutics Inc Stock (QNCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Quince Therapeutics Inc Stock (QNCX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Benatti Luca | Director |
Dec 26 '25 |
Sale |
3.47 |
50,000 |
173,500 |
39,179 |
| Hannah Brendan | CBO, COO & CCO |
Dec 05 '25 |
Option Exercise |
0.91 |
27,551 |
25,012 |
361,827 |
3.00%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):